e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Diffuse pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung cancer in patients with idiopathic pulmonary fibrosis:
Clinical characteristics and impact on survival
J. S. Park, T. Lee, J. Y. Park, H. Y. Lee, H. J. Lim, Y. J. Cho, H. I. Yoon, J. H. Lee, S. Jheon, C. G. Yoo, C. T. Lee, S. K. Han (Seongnam, Seoul, Republic Of Korea)
Source:
Annual Congress 2013 –Diffuse pulmonary fibrosis
Session:
Diffuse pulmonary fibrosis
Session type:
Thematic Poster Session
Number:
2328
Disease area:
Interstitial lung diseases, Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. S. Park, T. Lee, J. Y. Park, H. Y. Lee, H. J. Lim, Y. J. Cho, H. I. Yoon, J. H. Lee, S. Jheon, C. G. Yoo, C. T. Lee, S. K. Han (Seongnam, Seoul, Republic Of Korea). Lung cancer in patients with idiopathic pulmonary fibrosis:
Clinical characteristics and impact on survival
. Eur Respir J 2013; 42: Suppl. 57, 2328
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Imaging of eosinophilic lung disease
Related content which might interest you:
Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Neoplasia in patients with ILD; shortened survival
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Clinical profile of idiopathic pulmonary fibrosis with lung cancer
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis?
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Incidence, outcomes and risk factors for neoplasms in explanted lungs
Source: International Congress 2016 – Long-term outcomes of lung transplantation
Year: 2016
Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Possible indication for surgical resection of lung cancer associated with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014
Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012
Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014
Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Prognostic affect of the chronic obstructive pulmonary disease on the local-advanced stage non-small cell lung cancer
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
Source: International Congress 2016 – Orphan diseases II
Year: 2016
Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014
The impact of chronic obstructive pulmonary disease on survival of the patients with small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept